• Explore /
  • Poster
  • / Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).

Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).

Abstract Poster

Authors

null

Jung-min Lee

National Cancer Institute, National Institutes of Health, Bethesda, MD

Jung-min Lee , Joyce Liu , Peter L. Choyke , Osama Elbuluk , Ismail B. Turkbey , Jane B. Trepel , Min-Jung Lee , Liang Cao , Nicole D. Houston , Nicolas Gordon , William Douglas Figg , William Thomas Barry , Ursula Matulonis , Michael J. Birrer , Percy Ivy , Elise C. Kohn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01116648

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 5535)

DOI

10.1200/jco.2014.32.15_suppl.5535

Abstract #

5535

Poster Bd #

25

Abstract Disclosures

Similar Posters

First Author: Joyce F. Liu

First Author: Joyce F. Liu

First Author: Joyce Liu

First Author: B.J. Rimel